JMJD4 is a potential diagnostic and immunological biomarker in pan-cancer
DOI:
https://doi.org/10.54097/mbmqm498Keywords:
Jumonji domain containing 4 (JMJD4), pan-cancer, macrophage, stemness, epigenetic modulations, DNA damage repair.Abstract
During the development of cancer, many changes leading to a series of genetic mutations that cannot control tumor growth. Therefore, understanding the complex interactions between the intrinsic, extrinsic, and systemic mediators of tumor cells and disease progression is crucial for the rational development of effective anti-cancer treatments. In this study, we conducted a multi-omics pan-cancer exploration of the function of JMJD4 using various comprehensive analysis tools and samples collected from relevant cancer databases, to understand how JMJD4 affects pan-cancer development by identifying its clinical features and multi-omics heterogeneity. We discovered that JMJD4 was highly expressed and associated with cancer stemness, epigenetic modulations and DNA repair in pan-cancer, especially in BLCA, BRCA, CHOL, COAD, ESCA. JMJD4 was also related to most immune-infiltrating cells, which indicated that JMJD4 may serve as a diagnostic and immunological biomarker in pan-cancer. Therefore, JMJD4 can be used as an indicator and a new therapeutic target for early tumor diagnosis and a prognostic marker for many types of cancers.
Downloads
References
[1] Ciavardelli D, Bellomo M, Consalvo A, Crescimanno C, Vella V. Metabolic Alterations of Thyroid Cancer as Potential Therapeutic Targets. Biomed Res Int. 2017; 2017: 2545031.
[2] Gupta P, Kim B, Kim SH, Srivastava SK. Molecular targets of isothiocyanates in cancer: recent advances. Mol Nutr Food Res. 2014 Aug; 58 (8): 1685 - 707.
[3] Reher D, Klink B, Deutsch A, Voss-Böhme A. Cell adhesion heterogeneity reinforces tumour cell dissemination: novel insights from a mathematical model. Biol Direct. 2017 Aug 11; 12 (1): 18.
[4] Liang X, Zhang H, Wang Z, Zhang X, Dai Z, Zhang J, Luo P, Zhang L, Hu J, Liu Z, et al. JMJD8 Is an M2 Macrophage Biomarker, and It Associates with DNA Damage Repair to Facilitate Stemness Maintenance, Chemoresistance, and Immunosuppression in Pan-Cancer. Front Immunol. 2022, 11; 13: 875786.
[5] Yeo KS, Tan MC, Lim YY, Ea CK. JMJD8 is a Novel Endoplasmic Reticulum Protein with a JmjC Domain. Sci Rep. 2017, 7 (1): 15407.
[6] Tang Y, Feng M, Su Y, Ma T, Zhang H, Wu H, Wang X, Shi S, Zhang Y, Xu Y, Hu S, Wei K, Xu D. Jmjd4 Facilitates Pkm2 Degradation in Cardiomyocytes and Is Protective Against Dilated Cardiomyopathy. Circulation. 2023 May 30; 147 (22): 1684 - 1704.
[7] Yan H, Bao Y, Lin Z. High Expression of JMJD4 Is a Potential Diagnostic and Prognostic Marker of Renal Cell Carcinoma. Dis Markers. 2021 Dec 24; 2021: 9573540.
[8] Ho YJ, Shih CP, Yeh KT, Shi B, Gong Z, Lin YM, Lu JW. Correlation between high expression levels of jumonji domain-containing 4 and short survival in cases of colon adenocarcinoma. Biochem Biophys Res Commun. 2018 Sep 10; 503 (3): 1442 - 1449.
[9] Li Z, Zhou Y, Jia K, Yang Y, Zhang L, Wang S, Dong Y, Wang M, Li Y, Lu S, Zhang W, Zhang L, Fan Y, Zhang D, Li N, Yu Y, Cao X, Hou J. JMJD4-demethylated RIG-I prevents hepatic steatosis and carcinogenesis. J Hematol Oncol. 2022 Nov 4; 15 (1): 161. Ma Kunlong. Short term distributed load forecasting method based on big data. Changsha: Hunan University, 2014.
[10] Ho YJ, Shih CP, Yeh KT, Shi B, Gong Z, Lin YM, Lu JW. Correlation between high expression levels of jumonji domain-containing 4 and short survival in cases of colon adenocarcinoma. Biochem. Biophys. Res. Commun. 503 (2018) 1442 – 1449.
[11] CHEN X, SONG E. The theory of tumor ecosystem [J]. Cancer Commun (Lond), 2022, 42 (7): 587 - 608.
[12] Elhanani O, Ben-Uri R, Keren L. Spatial profiling technologies illuminate the tumor microenvironment. Cancer Cell. 2023 Mar 13; 41 (3): 404 - 420.
[13] Vitale I, Manic G, Coussens LM, Kroemer G, Galluzzi L. Macrophages and Metabolism in the Tumor Microenvironment. Cell Metab. 2019 Jul 2; 30 (1): 36 - 50.
[14] GAO Y, ROSEN JM, ZHANG XH. The tumor-immune ecosystem in shaping metastasis. Am J Physiol Cell Physiol, 2023, 324 (3): C707 - C717.
[15] CHARPENTIER M, SPADA S, VAN NEST SJ, et al. Radiation therapy-induced remodeling of the tumor immune microenvironment. Semin Cancer Biol, 2022, 86 (Pt 2): 737 - 747.
[16] BENAVENTE S, SANCHEZ-GARCIA A, NACHES S, et al. Therapy-induced modulation of the tumor microenvironment: New opportunities for cancer therapies. Front Oncol, 2020, 10: 582884.
[17] Manni W, Jianxin X, Weiqi H, Siyuan C, Huashan S. JMJD family proteins in cancer and inflammation. Signal Transduct Target Ther. 2022 Sep 1; 7 (1): 304.
[18] Oh S, Shin S, Janknecht R. The small members of the JMJD protein family: Enzymatic jewels or jinxes? Biochim Biophys Acta Rev Cancer. 2019 Apr;1871 (2): 406 - 418.
[19] Mantovani A, Allavena P, Marchesi F, Garlanda C. Macrophages as tools and targets in cancer therapy. Nat Rev Drug Discov. 2022 Nov; 21 (11): 799 - 820.
[20] DeNardo DG, Ruffell B. Macrophages as regulators of tumour immunity and immunotherapy. Nat Rev Immunol. 2019 Jun; 19 (6): 369 - 382.
[21] Park MD, Silvin A, Ginhoux F, Merad M. Macrophages in health and disease. Cell. 2022 Nov 10; 185 (23): 4259 - 4279.
[22] Dyachkova U, Vigovskiy M, Basalova N, Efimenko A, Grigorieva O. M2-Macrophage-Induced Chronic Inflammation Promotes Reversible Mesenchymal Stromal Cell Senescence and Reduces Their Anti-Fibrotic Properties. Int J Mol Sci. 2023 Dec 4; 24 (23): 17089. [22] Sun L, Wang X, Saredy J, Yuan Z, Yang X, Wang H. Innate-adaptive immunity interplay and redox regulation in immune response. Redox Biol. 2020 Oct; 37: 101759.
[23] Beroukhim R, Mermel CH, Porter D, Wei G, Raychaudhuri S, Donovan J, et al. The Landscape of Somatic Copy-Number Alteration Across Human Cancers. Nature (2010) 463 (7283): 899 – 905.
[24] Li T, Fu J, Zeng Z, Cohen D, Li J, Chen Q, et al. TIMER2.0 for Analysis of Tumor-Infiltrating Immune Cells. Nucleic Acids Res (2020) 48 (W1): W509 – w14.
[25] Tang Z, Kang B, Li C, Chen T, Zhang Z. GEPIA2: An Enhanced Web Server for Large-Scale Expression Profiling and Interactive Analysis. Nucleic Acids Res (2019) 47 (W1): W556 – w60.
[26] Chandrashekar DS, Bashel B, Balasubramanya SAH, Creighton CJ, PonceRodriguez I, Chakravarthi B, et al. UALCAN: A Portal for Facilitating Tumor Subgroup Gene Expression and Survival Analyses. Neoplasia (N Y NY) (2017) 19 (8): 649 – 58.
[27] Shen x, et al. 2022. Sangerbox: A comprehensive, interaction-friendly clinical bioinformatics analysis platform. iMeta 1 (3): e36.
[28] Cerami E, Gao J, Dogrusoz U, Gross BE, Sumer SO, Aksoy BA, et al. The Cbio Cancer Genomics Portal: An Open Platform for Exploring Multidimensional Cancer Genomics Data. Cancer Discov (2012) 2 (5): 401 – 4.
[29] Chun-Jie Liu, Fei-Fei Hu, Gui-Yan Xie, Ya-Ru Miao, Xin-Wen Li, Yan Zeng, An-Yuan Guo. GSCA: an Integrated Platform for Gene Set Cancer Analysis at Genomic, Pharmacogenomic, and Immunogenomic Levels. Briefings in bioinformatics, 2022, bbac558.
[30] Li T, Fu J, Zeng Z, Cohen D, Li J, Chen Q, et al. TIMER2.0 for Analysis of Tumor-Infiltrating Immune Cells. Nucleic Acids Res (2020) 48 (W1): W509 – w14.
[31] Li X, Liu G, Wu W. Recent Advances in Lynch Syndrome. Exp Hematol Oncol (2021) 10 (1): 37.
[32] Coleman RL, Oza AM, Lorusso D, Aghajanian C, Oaknin A, Dean A, et al. Rucaparib Maintenance Treatment for Recurrent Ovarian Carcinoma After Response to Platinum Therapy (ARIEL3): A Randomised, Double-Blind, Placebo-Controlled, Phase 3 Trial. Lancet (London England) (2017) 390 (10106): 1949 – 61.
[33] Malta TM, Sokolov A, Gentles AJ, Buczkowski T, Poisson L, Weinstein JN, et al. Machine Learning Identifies Stemness Features Associated with Oncogenic Dedifferentiation. Cell (2018) 173 (2): 338 – 54. e15.
[34] Dominissini D, Nachtergaele S, Moshitch-Moshkovitz S, Peer E, Kol N, BenHaim MS, et al. The Dynamic N (1)-Methyl adenosine Methylome in Eukaryotic Messenger RNA. Nature (2016) 530 (7591): 441 – 6.
[35] Pan T. N6-Methyl-Adenosine Modification in Messenger and Long Noncoding RNA. Trends Biochem Sci (2013) 38 (4): 204 – 9.
[36] Amort T, Rieder D, Wille A, Khokhlova-Cubberley D, Riml C, Trixl L, et al. Distinct 5-Methylcytosine Profiles in Poly (A) RNA From Mouse Embryonic Stem Cells and Brain. Genome Biol (2017) 18 (1): 1.
[37] Zhang Y, Yao X, Zhou H, Wu X, Tian J, Zeng J, et al. OncoSplicing: An Updated Database for Clinically Relevant Alternative Splicing in 33 Human Cancers. Nucleic Acids Res (2022) 50 (D1): D1340 – d7.
[38] Szklarczyk D, Gable AL, Nastou KC, Lyon D, Kirsch R, Pyysalo S, et al. The STRING Database in 2021: Customizable Protein-Protein Networks, and Functional Characterization of User-Uploaded Gene/Measurement Sets. Nucleic Acids Res (2021) 49 (D1): D605 – d12.
[39] Zhang Y, Chen F, Donehower LA, Scheurer ME, Creighton CJ. A Pediatric Brain Tumor Atlas of Genes Deregulated by Somatic Genomic Rearrangement. Nat Commun (2021) 12 (1): 937.
[40] Liberzon A, Subramanian A, Pinchback R, Thorvaldsdottir H, Tamayo P, Mesirov JP. Molecular Signatures Database (MSigDB) 3.0. Bioinf (Oxford England) (2011) 27 (12): 1739 – 40.
[41] Thorsson V, Gibbs DL, Brown SD, Wolf D, Bortone DS, Ou Yang TH, et al. The Immune Landscape of Cancer. Immunity (2018) 48 (4): 812 – 30. e14.
[42] Ru B, Wong CN, Tong Y, Zhong JY, Zhong SSW, Wu WC, et al. TISIDB: An Integrated Repository Portal for Tumor-Immune System Interactions. Bioinf (Oxford England) (2019) 35 (20): 4200 – 2.
[43] Zeng Z, Wong CJ, Yang L, Ouardaoui N, Li D, Zhang W, et al. TISMO: Syngeneic Mouse Tumor Database to Model Tumor Immunity and Immunotherapy Response. Nucleic Acids Res (2022) 50 (D1): D1391 – d7.
[44] Fan Z, Chen R, Chen X. SpatialDB: A Database for Spatially Resolved Transcriptomes. Nucleic Acids Res (2020) 48 (D1): D233 – d7.
[45] Sun D, Wang J, Han Y, Dong X, Ge J, Zheng R, et al. TISCH: A Comprehensive Web Resource Enabling Interactive Single-Cell Transcriptome Visualization of Tumor Microenvironment. Nucleic Acids Res (2021) 49 (D1): D1420 – d30.
[46] Newman AM, Liu CL, Green MR, Gentles AJ, Feng W, Xu Y, et al. Robust Enumeration of Cell Subsets from Tissue Expression Profiles. Nat Methods (2015) 12 (5): 453 – 7.
[47] Amendola PG, Zaghet N, Ramalho JJ, Vilstrup Johansen J, Boxem M, Salcini AE. JMJD-5/KDM8 Regulates H3K36me2 and Is Required for Late Steps of Homologous Recombination and Genome Integrity. PloS Genet (2017) 13 (2): e1006632.
[48] Lee C, Hong S, Lee MH, Koo HS. A PHF8 homolog in C. elegans promotes DNA repair via homologous recombination. PLoS One. 2015 Apr 8; 10 (4): e0123865.
[49] Amendola PG, Zaghet N, Ramalho JJ, Vilstrup Johansen J, Boxem M, Salcini AE. JMJD-5/KDM8 regulates H3K36me2 and is required for late steps of homologous recombination and genome integrity. PLoS Genet. 2017 Feb 16; 13 (2): e1006632.
[50] Liang X, Zhang H, Wang Z, Zhang X, Dai Z, Zhang J, Luo P, Zhang L, Hu J, Liu Z, Bi C, Cheng Q. JMJD8 Is an M2 Macrophage Biomarker, and It Associates with DNA Damage Repair to Facilitate Stemness Maintenance, Chemoresistance, and Immunosuppression in Pan-Cancer. Front Immunol. 2022 Jul 11; 13: 875786. doi: 10.3389/fimmu.2022.875786. PMID: 35898493; PMCID: PMC9309472.
Downloads
Published
Issue
Section
License
Copyright (c) 2025 Highlights in Science, Engineering and Technology
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
How to Cite
